CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $84,510 | +43.8% | 5,668 | +5.6% | 0.00% | +33.3% |
Q2 2023 | $58,780 | +208.2% | 5,368 | -12.5% | 0.00% | +200.0% |
Q1 2022 | $19,071 | -73.9% | 6,132 | -69.4% | 0.00% | 0.0% |
Q3 2021 | $73,150 | -28.1% | 20,041 | -10.5% | 0.00% | -50.0% |
Q1 2021 | $101,710 | +66.9% | 22,403 | +111.1% | 0.00% | +100.0% |
Q4 2020 | $60,924 | -43.4% | 10,614 | -28.6% | 0.00% | -50.0% |
Q3 2020 | $107,666 | +28.2% | 14,871 | -38.2% | 0.00% | +100.0% |
Q2 2020 | $84,015 | -20.3% | 24,073 | +16.9% | 0.00% | -50.0% |
Q3 2019 | $105,467 | -26.0% | 20,599 | +3.5% | 0.00% | 0.0% |
Q2 2019 | $142,484 | -46.1% | 19,900 | 0.0% | 0.00% | -60.0% |
Q1 2019 | $264,272 | +68.7% | 19,900 | 0.0% | 0.01% | +66.7% |
Q4 2018 | $156,613 | -29.0% | 19,900 | 0.0% | 0.00% | -25.0% |
Q3 2018 | $220,492 | -99.9% | 19,900 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $267,058,000 | – | 19,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |